<DOC>
	<DOC>NCT01025544</DOC>
	<brief_summary>This study will evaluate the safety and immunogenicity of booster doses of the two vaccines used to prevent Haemophilus influenzae type b infections in children 12-18 months of age.</brief_summary>
	<brief_title>Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Haemophilus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Toddlers 1218 months of age who have previously participated in study M37P2. Prior Hib booster administration. History of serious reaction(s) following vaccination. Vaccination within 14 days of study vaccination. Known or suspected immune impairment. For additional entry criteria please refer to the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Haemophilus influenzae type b (Hib)</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Booster</keyword>
</DOC>